Biogen has finalised a $900 million payment to settle a whistleblower lawsuit claiming that it paid kickbacks to US doctors to prescribe its multiple sclerosis drugs.

Investors with a lot of money to spend have taken a bullish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the trades showed up on publicly available ...